Phaseline

Companies › Shanghai Minwei Biotechnology

Shanghai Minwei Biotechnology: clinical trials, targets and expected readouts

4 active drug programs in 9 registered trials: 5 Phase 1, 4 Phase 2; Metabolic and endocrine, Cardiovascular, Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MWN109 2
GLP-1 receptor agonist
GLP1RPhase 2Overweight , Obesity; Type 2 Diabetes Mellitus (T2DM); Overweight or Obese; Overweight or ObesityNov 2026
MWX203
APOC3 inhibitor
–Phase 2Mixed Dyslipidemia; Healthy VolunteersJan 2027
MWX401
Unclear - specific mechanism not stated in registry entry
–Phase 1Essential HypertensionDec 2026
MWN105–Phase 1Overweight , ObesityJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06859853MWN109 2Phase 1Overweight or ObeseMetabolic and endocrineSep 2025
NCT06938269MWN109 2Phase 1Overweight or ObesityMetabolic and endocrineMar 2026
NCT07804797MWN109 2Phase 2Overweight , ObesityMetabolic and endocrineSep 2026
NCT07791537MWN109 2Phase 2Overweight , ObesityMetabolic and endocrineNov 2026
NCT07803835MWX401Phase 1Essential HypertensionCardiovascularDec 2026
NCT07803809MWN105Phase 1Overweight , ObesityMetabolic and endocrineJan 2027
NCT07799025MWX203Phase 1Healthy VolunteersOtherJan 2027
NCT07801820MWN109 2Phase 2Type 2 Diabetes Mellitus (T2DM)Metabolic and endocrineMar 2027
NCT07803822MWX203Phase 2Mixed DyslipidemiaCardiovascularFeb 2028

Targets

GLP1R (1)

Companies with the same targets

Eli Lilly Novo Nordisk Roche Hangzhou Sciwind Biosciences Hangzhou Zhongmei Huadong Pharmaceutical Hanmi Pharmaceutical Company AstraZeneca Amgen Regeneron Pharmaceuticals Green Valley (Shanghai) Pharmaceuticals

Companies built like this

Beijing QL Biopharmaceutical Fujian Shengdi Pharmaceutical Chendu DIAO Pharmaceutical Group Verdiva Bio Dev Sirius Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.